Two Novel Immunotherapy Agents Targeting DLL3 in SCLC: Trials in Progress of AMG 757 and AMG 119

被引：5
|
作者：
Owonikoko, T. [1 ]
Smit, M. [2 ]
Borghaei, H. [3 ]
Salgia, R. [4 ]
Boyer, M. [5 ]
Rasmussen, E. [6 ]
Byers, L. [7 ]
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA
[2] Amgen Inc, Translat Sci, Thousand Oaks, CA 91320 USA
[3] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[4] Dept Med Oncol & Therapeut Res, Duarte, CA USA
[5] Chris Brien Lifehouse, Camperdown, NSW, Australia
[6] Amgen Inc, Biostat Sci, Thousand Oaks, CA 91320 USA
[7] MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
D O I：
10.1016/j.jtho.2018.08.307
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA13.02
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 15 条
  • [1] Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC
    Giffin, M.
    Cooke, K.
    Lobenhofer, E.
    Friedrich, M.
    Raum, T.
    Coxon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S971 - S971
  • [2] Nonclinical Safety Assessment of AMG 757, a DLL3 Bispecific T Cell Engager, in the Cynomolgus Monkey
    Lobenhofer, E.
    Werner, J.
    Giffin, M.
    Engwall, M.
    Davies, R.
    Homann, O.
    Lafleur, M.
    Moffat, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S541 - S541
  • [3] Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).
    Byers, Lauren Averett
    Chiappori, Alberto
    Smit, Marie-Anne Damiette
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
    Owonikoko, T.
    Boyer, M.
    Johnson, M.
    Govindan, R.
    Rodrigues, L.
    Blackhall, F.
    Boosman, R.
    Champiat, S.
    Hummel, H.
    Lai, W. V.
    Udagawa, H.
    Chiang, A.
    Dowlati, A.
    Hann, C.
    Salgia, R.
    Vokes, E.
    Minocha, M.
    Sadraei, N.
    Shetty, A.
    Smit, M.
    Zhang, Y.
    Sable, B.
    Pati, A.
    Roy, S.
    Borghaei, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S126 - S126
  • [5] Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
    Smit, Marie-Anne Damiette
    Borghaei, Hossein
    Owonikoko, Taofeek Kunle
    Hummel, Horst-Dieter
    Johnson, Melissa Lynne
    Champiat, Stephane
    Salgia, Ravi
    Udagawa, Hibiki
    Boyer, Michael J.
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] AMG 757, A HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNE THERAPY AGAINST DLL3 IN SCLC: PHASE 1 INTERIM RESULTS
    Borghaei, Hossein
    Boyer, Michael
    Johnson, Melissa
    Govindan, Ramaswamy
    Rodrigues, Luis Paz-Ares
    Blackhall, Fiona
    Boosman, Rene
    Champiat, Stephane
    Hummel, Horst-Dieter
    Lai, W. Victoria
    Udagawa, Hibiki
    Chiang, Anne
    Dowlati, Afshin
    Hann, Christine
    Salgia, Ravi
    Vokes, Everett
    Minocha, Mukul
    Hashemi-Sadraei, Nooshin
    Shetty, Aditya
    Smit, Marie-Anne Damiette
    Yang, Hui
    Owonikoko, Taofeek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A219 - A220
  • [7] Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
    Owonikoko, Taofeek Kunle
    Borghaei, Hossein
    Champiat, Stephane
    Paz-Ares, Luis G.
    Govindan, Ramaswamy
    Boyer, Michael J.
    Johnson, Melissa Lynne
    Udagawa, Hibiki
    Hummel, Horst-Dieter
    Salgia, Ravi
    Blackhall, Fiona Helen
    Boosman, Rene J.
    Lai, Wei-Chu Victoria
    Dowlati, Afshin
    Vokes, Everett E.
    Hann, Christine L.
    Chiang, Anne C.
    Endraca, Marichu
    Soman, Neelesh
    Smit, Marie-Anne Damiette
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
    Cooke, K.
    Estrada, J.
    Zhan, J.
    Werner, J.
    Bailis, J.
    Hughes, P.
    Shetty, A.
    Canon, J.
    Smit, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S343 - S344
  • [9] Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
    Paz-Ares, L.
    Owonikoko, T. K.
    Johnson, M.
    Govindan, R.
    Izumi, H.
    Lai, V.
    Borghaei, H.
    Boyer, M.
    Boosman, R. J.
    Hummel, H-D.
    Blackhall, F.
    Dowlati, A.
    Zhang, Y.
    Mukherjee, S.
    Sable, B.
    Pati, A.
    Shetty, A.
    Sadraei, N. Hashemi
    Champiat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S720 - S721
  • [10] Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE®) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC)
    Cooke, Keegan
    Estrada, Juan
    Zhan, Jinghui
    Werner, Jonathan
    Caenepeel, Sean
    Giffin, Mike
    Bailis, Julie M.
    Coxon, Angela
    Hughes, Paul E.
    Canon, Jude
    CANCER RESEARCH, 2020, 80 (16)
12